Preview

Rational Pharmacotherapy in Cardiology

Advanced search

STATINS AND RISK OF INFECTIOUS DISEASES

https://doi.org/10.20996/1819-6446-2013-9-3-306-310

Full Text:

Abstract

Besides hypolipidemic effect statins demonstrate some not-lipid (pleotropic) ones. Special attention has been paying to statin inducing reduction in bacterial infections incidence and severity, and pneumonia particularly. Results of the large studies on statin influence on infectious disease are presented.

About the Authors

O. M. Drapkina
I.M. Sechenov First Moscow State Medical University, Moscow
Russian Federation


R. N. Shepel'
I.M. Sechenov First Moscow State Medical University, Moscow
Russian Federation


References

1. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32(14):1769–818.

2. Tonolo G, Ciccarese M, Brizzi P. Plasma lipoprotein and renal function during simvastatin treatment.Diabetologia 1999; 38:447–51.

3. Bonetti P.O., Lerman V.O., Napoli C., Lerman A. Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J 2003; 24(3): 225—248.

4. Schlienger RG, Fedson DS, Jick SS, et al. Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy 2007;27:325–32.

5. van de Garde EM, Hak E, Souverein PC, et al. Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax 2006;61:957–61.

6. Myles PR, Hubbard RB, McKeever TM, et al. Risk of community-acquired pneumonia and the use of statins, ACE inhibitors and gastric acid suppressants: a population-based case-control study. Pharmacoepidemiol Drug Saf 2009;18:269–75.

7. Terblanche M, Almog Y, Rosenson RS, et al. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis 2007;7(5):358–368.

8. Dechend R, Gieffers J, Dietz R, et al. Hydroxymethylglutaryl coenzyme A reductase inhibition reduces Chlamydia pneumoniae-induced cell interaction and activation. Circulation 2003;108(3):261–265.

9. van de Garde EMW, Hak E, Souverein PC, et al. Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax 2006;61(11):957–961.

10. Montecucco F, Mach F. Update on statin-mediated anti-inflammatory activities in atherosclerosis. Semin Immunopathol 2009;31(1):127–142.

11. Merx MW, Liehn EA, Graf J, et al. Statin treatment after onset of sepsis in a murine model improves survival. Circulation 2005;112(1):117–124.

12. Jerwood S, Cohen J. Unexpected antimicrobial effect of statins. J Antimicrob Chemother 2008;61(12):362–364.

13. Ridker P.M., Danielson E., Fonseca F.A.H., et al. Rosuvastatin to Prevent Vascular Events in Men and

14. Women with Elevated C-Reactive Protein. N Engl J Med 2008;359:2195–2207

15. Novack V., MacFadyen J., Malhotra A. et al. The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial. CMAJ 2012; 184(7): E367–72

16. Vinogradova Y, Coupland C, Hippisley-Cox J. Risk of pneumonia in patients taking statins: populationbased nested case-control study. Br J Gen Pract 2011; 61(592): e742–e748.

17. Thomsen R.W., Riis A., Kornum J., et al. Preadmission use of statins and outcomes after hospitalization with pneumonia. Arch Intern Med 2008; 168: 2081–2087.

18. Daniels KR, Mansi IA, Magulick JP et al. The Impact of Statins on the Incidence of Bacteremia and Pneumonia in Military Personnel. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC): Presentation L1–297. San Francisco September 9–12, 2012.


For citation:


Drapkina O.M., Shepel' R.N. STATINS AND RISK OF INFECTIOUS DISEASES. Rational Pharmacotherapy in Cardiology. 2013;9(3):306-310. (In Russ.) https://doi.org/10.20996/1819-6446-2013-9-3-306-310

Views: 488


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)